Programme: Horizon Europe – Marie Skłodowska-Curie Actions (MSCA) Staff Exchanges
Grant Agreement: 101299576
Duration: 48 Months
MagBIO is an ambitious international research and innovation project developing a new generation of living magnetobots for targeted theranostic applications against metastatic solid tumours. Bringing together 18 partners from Europe and the United States, the project combines expertise from academia, industry, regulatory science, sustainability assessment, and healthcare innovation to advance personalised and responsible medical technologies.
The project focuses on engineering living magnetobots inspired by magnetotactic bacteria, microorganisms capable of sensing and responding to magnetic fields. These innovative biological systems are being developed to deliver therapeutic payloads directly to tumour sites while simultaneously supporting diagnostic imaging capabilities. By integrating therapy and diagnosis within a single platform, MagBIO aims to improve the treatment of major cancers, including pancreatic, breast, lung, and colorectal tumours.
A defining feature of MagBIO is its commitment to embedding sustainability, safety, and regulatory readiness from the earliest stages of technology development. Through a multidisciplinary and intersectoral approach, the project seeks to ensure that future theranostic technologies are not only clinically effective but also environmentally sustainable, socially responsible, and economically viable.
Europe for Business (EFB) plays a central role in the consortium as leader of Work Package 4: Safe and Sustainable by Design (SSbD) Magnetobots. EFB coordinates activities focused on regulatory compliance, sustainability assessment, life cycle thinking, and responsible innovation pathways for emerging healthcare technologies.
Within WP4, EFB leads the development of strategies for regulatory compliance and safety hotspot identification, supports rapid assessments of human health and environmental risks, and contributes scientific leadership to Life Cycle Assessment (LCA), Social Life Cycle Assessment (S-LCA), and Life Cycle Costing (LCC) activities. These assessments will provide evidence-based guidance for improving the environmental, social, and economic performance of magnetobot technologies throughout their development journey.
EFB is also responsible for key project deliverables related to magnetobot biomanufacturing inventory data, life cycle assessment, and techno-economic evaluation. In addition, EFB contributes expertise in exploitation strategy, business modelling, stakeholder engagement, and communication activities to support the future uptake and impact of project results.
Through international staff exchanges and knowledge transfer activities involving 34 Early-Stage Researchers and 33 Experienced Researchers, MagBIO is building the next generation of interdisciplinary experts capable of addressing complex healthcare challenges while advancing sustainable innovation practices.
By combining cutting-edge biotechnology, personalised medicine, sustainability assessment, and responsible innovation principles, MagBIO aims to contribute to safer, more effective, and more sustainable healthcare solutions for patients in Europe and beyond.
PROJECT NEWS
2025 © Europe for Business (EFB) All Rights Reserved. | Powered By Webpristine Technology